Gapping up
In reaction to earnings/guidance:
- AXNX +5.7%, VSCO +5%, PI +4.6%, INMD +1.7%, TNDM +1.3%, DNA +1.3%, XRAY +1%
Other news:
- PROK +25.4% (announces publication of trial design for Phase 2 trial of REACT)
- MASI +7.5% (ITC Judge rules Apple violated U.S. Trade Laws by infringing Masimo Pulse Oximeter Patent)
- HKD +5.9% (receives further confirmation that parties will not sell shares before Aug 2024)
- WWE +5.3% (Board of Directors unanimously elects Vince McMahon Executive Chairman)
- FFIN +5% (names new CFO)
- BTAI +3.4% (top-line data from its Phase 2 trial of BXCL701 in combination with KEYTRUDA in small cell neuroendocrine metastatic castration-resistant prostate cancer patients)
- BLND +2.9% (announces strategic and financial initiatives to achieve path to profitability)
- VSAT +2.9% (awarded China certificate to install satellite connectivity system on Boeing 737 series)
- MNOV +2.9% (receives a notice of allowance for a new patent covering MN-001 and MN-002)
- GATO +2.7% (reports record silver production and exceeds 2022 production guidance)
- TSLA +2% (files for $717 mln expansion of Gigafactory Texas according to Electrek)
- CONN +2% (FRG is considering going private also eyeing potential deal to acquire CONN both according to WSJ)
Analyst comments:
- CC +2.2% (upgraded to Buy from Neutral at BofA Securities)
- BX +1.9% (upgraded to Overweight from Equal Weight at Wells Fargo)
- WBD +1.8% (upgraded to Buy from Neutral at Guggenheim)